Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Linagliptin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172222

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Metformin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172248

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium bromide

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63127

Registration Number: NCT02172482

Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: IVAX Warfarin
Drug: BMS Coumadin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02171494

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Losartan
Drug: Hydrochlorothiazide

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 363

Registration Number: NCT02172586

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Sitagliptin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172196

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: dabigatran etexilate
Drug: quinidine

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT02171624

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992
Drug: Docetaxel

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT02171741

Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran high dose
Drug: Dabigatran low dose

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02171468

Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium inhalation powder capsule
Drug: Ipratropium Bromide Metered Dose Inhaler
Drug: Placebo Metered Dose Inhaler
Drug: Placebo inhalation powder capsule

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 215

Registration Number: NCT02172469

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy